IKT

1.3201.54%
JA

John Adams

Chief Scientific Officer

Dr. John Adams, Ph.D., is Chief Scientific Officer of Inhibikase Therapeutics, Inc. from February 2025. Dr. Adams joined the Inhibikase Therapeutics, Inc. in February 2025. He was Senior Vice President of Discovery Biology of Iambic Therapeutics, Inc. until 2024. He has joined Inhibikase from CorHepta where he was co-founder and Chief Scientific Officer. Previously he was Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals and the Head of Research at Arena Pharmaceuticals. Dr. Adams earned his PhD in Physiological Science at UCLA and his B.S. Biological Sciences from U.C. Santa Barbara.

Positions